Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2007 pp 369–385Cite as

Antihypertonika

  • Chapter

  • 556 Accesses

Auszug

In diesem Kapitel zu speziellen Antihypertonika werden neben den Empfehlungen zur antihypertensiven Therapie Alpharezeptorenblocker und zentral wirkende Antisympathikotonika sowie Kombinationspräparate von Betarezeptorenblockern und Calciumantagonisten dargestellt.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, München.

    Google Scholar 

  • Anlauf M, Hense HW (2003): Echte und vermeintliche Sparpotenziale in der Hochdrucktherapie — Neues aus dem Zauberhut. Dtsch Med Wschr 128: 1557–1559.

    PubMed  CAS  Google Scholar 

  • Anlauf M, Weber F (2005): Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention in Bundesärztekammer Berlin (Hrgs): Fortschritt und Fortbildung in der Medizin, Band 29, Deutscher Ärzte-Verlag, Köln.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), 2. Auflage. Im Internet: AVP.www. akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTT 2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964.

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958.

    Article  CAS  Google Scholar 

  • Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571.

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N et al (2003): Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667.

    Article  PubMed  CAS  Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro.umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906.

    Article  PubMed  CAS  Google Scholar 

  • Davis BD, Piller LB, Cutler JA, Curt Furberg C et al. (2006): Role of diuretics in the prevention of heart failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210.

    Article  PubMed  CAS  Google Scholar 

  • Deutsche Liga zur Bekämpfung des hohen Blutdrucks (2003): Empfehlungen zur Therapie der arteriellen Hypertonie. Heidelberg.

    Google Scholar 

  • Elliott WJ, Meyer PM (2007).: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet; 369: 201–207.

    Article  PubMed  CAS  Google Scholar 

  • Guidelines Committee (2003): 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053.

    Article  Google Scholar 

  • Guidelines Task Force (2007): 2007 Guidelines for the Management of Artesiol Hypertension. J Hypertens 25: 1105–1187.

    Article  CAS  Google Scholar 

  • Kostis JB, Wilson AC, Freudenberger RS, et al. (2005): Long-term e. ect of diureticbased therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29–35.

    Article  PubMed  CAS  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553.

    Article  PubMed  CAS  Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension (partial update of CG18). London: Royal College of Physicians. Im Internet: http:// guidance.nice.org.uk/CG34/guidance/pdf/English

    Google Scholar 

  • Rothwell PM, Coull AJ, Silver LE, Fairhead JF et al (2005): Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783.

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG et al (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Gasowski J, Wang Lj G, Thijs L et al (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872.

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Birkenhäger WH (2005): Evidence that new antihypertensives are superior to older drugs. Lancet 366: 869–871.

    Article  PubMed  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967–1975.

    Article  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288: 2981–2997.

    Article  Google Scholar 

  • Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10: 1103–1109.

    Article  CAS  Google Scholar 

  • Verdecchia P, Reboldi G, Angeli F, Borgioni C et al (2004): Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension 43: 963–969.

    Article  PubMed  CAS  Google Scholar 

  • Weiland SK, Rapp K, Klenk J, Keil U (2006): Zunahme der Lebenserwartung — Größenordnung, Determinanten und Perspektiven. Dtsch Ärztebl 103: A 1072–A 1077.

    Google Scholar 

  • Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. (2007): Beta-blockers for hypertension (Review). Cochrane Database Syst Rev. 2007 Jan 24;(1): CD002003.

    Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.

    Article  PubMed  CAS  Google Scholar 

  • Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW et al (2003): Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289: 2363–2369.

    Article  PubMed  Google Scholar 

  • Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126: 1522–1530.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Anlauf, M. (2008). Antihypertonika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation